Literature DB >> 22458604

Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk.

Xaver Koenig1, Michael Kovar1, Stefan Boehm1, Walter Sandtner2, Karlheinz Hilber1.   

Abstract

Ibogaine, an alkaloid derived from the African shrub Tabernanthe iboga, has shown promising anti-addictive properties in animals. Anecdotal evidence suggests that ibogaine is also anti-addictive in humans. Thus, it alleviates drug craving and impedes relapse of drug use. Although not licensed as therapeutic drug, and despite evidence that ibogaine may disturb the rhythm of the heart, this alkaloid is currently used as an anti-addiction drug in alternative medicine. Here, we report that therapeutic concentrations of ibogaine reduce currents through human ether-a-go-go-related gene potassium channels. Thereby, we provide a mechanism by which ibogaine may generate life-threatening cardiac arrhythmias.
© 2012 The Authors, Addiction Biology © 2012 Society for the Study of Addiction.

Entities:  

Keywords:  Anti-addiction drug; QT interval prolongation; cardiac arrhythmias; hERG potassium channels; ibogaine; indole alkaloid

Mesh:

Substances:

Year:  2012        PMID: 22458604      PMCID: PMC4888945          DOI: 10.1111/j.1369-1600.2012.00447.x

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  9 in total

Review 1.  Ibogaine: a review.

Authors:  K R Alper
Journal:  Alkaloids Chem Biol       Date:  2001

2.  Addiction research. Ibogaine therapy: a 'vast, uncontrolled experiment'.

Authors:  Brian Vastag
Journal:  Science       Date:  2005-04-15       Impact factor: 47.728

3.  Long-QT syndrome induced by the antiaddiction drug ibogaine.

Authors:  Dianne W M Hoelen; Wilko Spiering; Gerlof D Valk
Journal:  N Engl J Med       Date:  2009-01-15       Impact factor: 91.245

Review 4.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

Authors:  W S Redfern; L Carlsson; A S Davis; W G Lynch; I MacKenzie; S Palethorpe; P K S Siegl; I Strang; A T Sullivan; R Wallis; A J Camm; T G Hammond
Journal:  Cardiovasc Res       Date:  2003-04-01       Impact factor: 10.787

5.  Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.

Authors:  D C Mash; C A Kovera; J Pablo; R F Tyndale; F D Ervin; I C Williams; E G Singleton; M Mayor
Journal:  Ann N Y Acad Sci       Date:  2000-09       Impact factor: 5.691

6.  Effects of duramycin on cardiac voltage-gated ion channels.

Authors:  Eva Zebedin; Xaver Koenig; Miroslav Radenkovic; Halyna Pankevych; Hannes Todt; Michael Freissmuth; Karlheinz Hilber
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-05       Impact factor: 3.000

Review 7.  hERG potassium channels and cardiac arrhythmia.

Authors:  Michael C Sanguinetti; Martin Tristani-Firouzi
Journal:  Nature       Date:  2006-03-23       Impact factor: 49.962

Review 8.  Mechanisms of antiaddictive actions of ibogaine.

Authors:  S D Glick; I S Maisonneuve
Journal:  Ann N Y Acad Sci       Date:  1998-05-30       Impact factor: 5.691

Review 9.  Medication development of ibogaine as a pharmacotherapy for drug dependence.

Authors:  D C Mash; C A Kovera; B E Buck; M D Norenberg; P Shapshak; W L Hearn; J Sanchez-Ramos
Journal:  Ann N Y Acad Sci       Date:  1998-05-30       Impact factor: 5.691

  9 in total
  13 in total

1.  An Ethical Exploration of Barriers to Research on Controlled Drugs.

Authors:  Michael H Andreae; Evelyn Rhodes; Tyler Bourgoise; George M Carter; Robert S White; Debbie Indyk; Henry Sacks; Rosamond Rhodes
Journal:  Am J Bioeth       Date:  2016       Impact factor: 11.229

Review 2.  Legal highs: staying on top of the flood of novel psychoactive substances.

Authors:  David Baumeister; Luis M Tojo; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2015-04

3.  Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study.

Authors:  Thomas Knuijver; Arnt Schellekens; Maarten Belgers; Rogier Donders; Toon van Oosteren; Kees Kramers; Robbert Verkes
Journal:  Addiction       Date:  2021-08-09       Impact factor: 7.256

Review 4.  The anti-addiction drug ibogaine and the heart: a delicate relation.

Authors:  Xaver Koenig; Karlheinz Hilber
Journal:  Molecules       Date:  2015-01-29       Impact factor: 4.411

Review 5.  Ibogaine and addiction in the animal model, a systematic review and meta-analysis.

Authors:  M Belgers; M Leenaars; J R Homberg; M Ritskes-Hoitinga; A F A Schellekens; C R Hooijmans
Journal:  Transl Psychiatry       Date:  2016-05-31       Impact factor: 6.222

6.  Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes.

Authors:  Deborah C Mash; Linda Duque; Bryan Page; Kathleen Allen-Ferdinand
Journal:  Front Pharmacol       Date:  2018-06-05       Impact factor: 5.810

7.  Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.

Authors:  Eduardo Ekman Schenberg
Journal:  Front Pharmacol       Date:  2018-07-05       Impact factor: 5.810

Review 8.  The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.

Authors:  Rishab N Iyer; David Favela; Guoliang Zhang; David E Olson
Journal:  Nat Prod Rep       Date:  2021-03-04       Impact factor: 13.423

9.  Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: a study to assess the drug's cardiac ion channel profile.

Authors:  Xaver Koenig; Michael Kovar; Lena Rubi; Agnes K Mike; Peter Lukacs; Vaibhavkumar S Gawali; Hannes Todt; Karlheinz Hilber; Walter Sandtner
Journal:  Toxicol Appl Pharmacol       Date:  2013-05-22       Impact factor: 4.219

10.  Anti-addiction Drug Ibogaine Prolongs the Action Potential in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Lena Rubi; Daniel Eckert; Stefan Boehm; Karlheinz Hilber; Xaver Koenig
Journal:  Cardiovasc Toxicol       Date:  2017-04       Impact factor: 3.231

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.